Non-steroidal anti-inflammatory drugs (NSAIDs) and gastro-intestinal toxicity: Current issues

Irish Journal of Medical Science

Volumn 168, Issue 4, 1999, Pages 242-245

  Shah, A A ^a   Fitzgerald, D J ^a   Murray, F E ^b  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b BEAUMONT HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FLOSULIDE; INDOMETACIN; KETOPROFEN; MELOXICAM; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PROSTACYCLIN; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROTON PUMP INHIBITOR; STOMACH SECRETION INHIBITOR; SUCRALFATE; SULINDAC;

ANALGESIC ACTIVITY; ANEMIA; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG FATALITY; DRUG SELECTIVITY; ENZYME INHIBITION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HUMAN; MORBIDITY; MORTALITY; OSTEOARTHRITIS; REVIEW; STOMACH EROSION; STOMACH ULCER;

EID: 0033390634     PISSN: 00211265     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02944348     Document Type: Review

References (42)

1. Rheumatoid arthritis: A double-blind comparison with indomethacin and placebo. International Journal of Clinical Pharmacology 1976; 13: 292-7.
2. Juul-moller, S., Edvardsson, N., Jahnmatz, B.et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 1992; 340: 1421-1425.
3. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither in 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-60.
4. Kirchheiner, B., Trang, L., Wellheim, F. A. Diclofenac sodium (Valtaren) in UK-TIA Study Group. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial. J. Neurol. Neurosurg. Psychiatry 1991; 54: 1044-54.
5. Bousser, M. G., Eschwege, E., Haguenau, M., Lefauconnier, J. M., Thibult, N., Touboul, D. et al. "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke 1983; 14:5-14.
6. Peleg, L, Maibach, H. T., Brown, S. H. et al. Aspirin and non-steroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch. Intern. Med. 1994; 154: 394-399.
7. Waddell, W. R. Loughry, R. W. Sulindac for polyposis of the colon. J. Surg. Oncol. 1983; 24: 83-87.
8. Bateman, D. N. NSAlDs: Time to re-evaluate gut toxicity. Lancet 1994; 343: 1051-52.
9. Paulus, H. E. PDS Arthritis Advisory Committee meeting: Post-marketing surveillance of NSAIDs. Arthritis Rheum. 1985; 28: 1168-69.
10. Walt, R., Katschinski, B., Logan, R., Ashley, J., Langman, M. Rising frequency of ulcer perforation in elderly people in United Kingdom. Lancet 1986; 1: 489-92.
11. Somerville, K., Faulkner G., Langman, M. NSAID and bleeding peptic ulcer. Lancet 1986; 1: 462-66.
12. Bjarnason, I., Zanelli, G., Prowse, P. et al. Blood and protein loss via small intestinal inflammation induced by non steroidal anti-inflammatory drugs. Lancet 1987; 2: 711-714.
13. Matsuhashi, N., Yamada, A., Hiraishi, M., Konishi, S., Minota, S., Saito, T., Sugano, K., Yazaki, Y., Min, M., Shiga, J. Multiple strictures of small intestine after long term NSAID drug therapy. Am. J. Gastroenterol. 1992; 87: 3-86.
14. Slattery, J., Warlow, C. P., Shorrock, C. J. et al. Risk of gastro-intestinal bleeding during secondary prevention of vascular events with Aspirin. Analysis of gastro-intestinal bleeding during UK-T.I.A. trial. Gut 1995; 37: 509-511.
15. Weil, J., Colin-Jones, D., Langman, M. J. S. et al. Prophylactic Aspirin and the risk of peptic ulcer bleeding. BMJ 1995; 310:827-30.
16. Rodriguez, L. A. G., Jick, H. Risk of upper gastrointestinal bleeding and perforation associated with individual NSAIDs. Lancet 1994; 343: 769-72.
17. Langman, M., Weil, J., Wainwright, P., Lawson, D. H., Rawlins, M. D., Logan, R. F. A., Murphy, M, Vessey, M. P., Colin-Jones, D. G. Risk of bleeding peptic ulcer associated with individual NSAIDs. Lancet 1994; 343: 1075-78.
18. Wallace, J. L., Tigley, A. W. New insights into prostaglandins and mucosal defence. Aliment. Pharmacol. Ther. 1995; 9: 227-235.
19. Ruppin, H., Person, B., Robert, A., Domschke, W. Gastric cytoprotection in man by Prostaglandin E2. Scand. J. Gastroenterol. 1981; 16: 647-52.
20. Kobayashi, K., Arakawa, T., Satoh, H., Fukuda, T., Nakamura, H. Effect of indomethacin, tiaprofenic acid diclofenac on rat gastric mucosal damage and content of prostacyclin and prostaglandin E2. Prostaglandins 1985; 30:609-18.
21. Saroseik, J., Mizuta, K., Slomiany, A. et al. Effect of acetylsalicylic acid on gastric mucin viscosity, permeability to hydrogen ions, and susceptibility to pepsin. Biochem. Pharmacol. 1986; 35: 4291-95.
22. Fantone, J. C. Mechanism of chemotactic factor stimulation of polymorphonuclear leukocytes: modulation by prostaglandins. In: Higgs, G. A., Williams, T. J., eds. Inflammatory mediators. London: MacMillan 1985: 127-48.
23. Feldman, M., Colturi, T. J. Effect on indomethacin on gastric acid and bicarbonate secretions in humans. Gastroenterology 1984; 87: 1339-43.
24. Selling, J. A., Hogan, D. L., Aly, A. et al. Indomethacin inhibits duodenal mucosal bicarbonate secretion and endogenous prostaglandin E2 output in human subjects. Ann. Intern. Med. 1987; 106: 368-71.
25. Allison, M., Howatson, M., Torrance, C., Lee, F., Russell, R. Gastro-intestinal damage associated with the use of NSAIDs. N. Engl. J. Med. 1992; 327: 749-754.
26. Xie, W., Robertson, D. L., Simmons, D. L. Mitogeninducible prostaglandin G/H synthase: a new target for NSAIDs. Drug Dev. Res. 1992; 25: 249-65.
27. Seibert, K., Zhang, Y., Leahy, K., Hauser, S. et al. Pharmacological and biochemical demonstration of the role of cyclo-oxygenase 2 in inflammation and pain. Proc. Natl. Acad. Sci. USA. 1994; 91: 12013-10217.
28. Vane, J. R., Mitchell, J. A., Appleton, I., Willoughby, D. A. et al. Inducible isoforms of cyclooxygenase and nitric oxide synthase in inflammation. Proc. Natl. Acad Sci. USA. 1994; 91:2046-2050.
29. Masferrer, J. L., Zweifel, B. S., Manning, P. T. et al. Selective inhibition of inducible cyclo-oxygenase 2 in vivo is anti-inflammatory and non ulcerogenic. Proc. Natl. Acad. Sci. USA. 1994; 91: 3228-3232.
30. Murray, F. E., Shah, A. A., Thjodleifsson, B., Oddsson, E., Gudjonsson, H., Sigthorsson, G., Crâne, R., Bjarason, I., Fitzgerald, D. J. Comparison of the effects of naproxen and the COX-2 selective NSAID nimesulide, on prostanoid formation in man. Gut 1998; 42 (Suppl. 1); A6.
31. Glaser, K., Sung, M. L., O'Neill, K., Belfast, M. et al. Etodolac selectively inhibits human PGHS-1 versus PGHS2. Eur. J. Phamacol. 1995; 281: 107-111.
32. Laine, L., Sloane, R., Ferretti, M., Cominelli, F. A randomized double blind comparison of placebo etodolac, and naproxen on gastrointestinal injury and psotaglandin production; Gastrointestinal Endoscopy. 1995; 42:428-33.
33. Cullun, L., Kelly, L., O'Conner, S., Fitzgerald, D. J. Nimesulide is selective COX-2 inhibitor in man. J. Pharmacol. Exp. Thcr. 1998; 287: 578-582.
34. Marini, U., Spotti, D. Gastric tolerability of nimesulide. A double-blind comparison of two dosage regimens and placebo. Drugs 1993; 46S: 249-52
35. Shah, A. A., Murray, F. E., Thjodleifsson, B., Oddsson, E., Gudjonsson, H., Sigthorsson, G., Bjarason, I., Fitzgerald, D. J. Nimesulide, a selective COX-2 inhibitor, cause less gastro-intestinal damage compared with naproxen: A prospective study in human volunteers. Gut 1998; 42 (Suppl. 1);A68.
36. Bjarason, I., MacPherson, A., Rotman, H., Schupp, J., Hayllar, J. A randomized, double-blind, cross over, competitive endoscopy study on the gastro-intestinal tolerability of a highly specific COX-2 inhibitor flosulide ,-, and naproxen. Scand. J. Gastroenterol. 1997; 32: 126-30.
37. Bjarnason, I., Hayllar, J., MacPherson, Russell A. S. Side effects of NSAIDs on the small and large intestine in humans. Gastroenterology 1993; 104: 1832-47.
38. Meling.T. R.,Aabakken, L.,Roseth, A., Osnes, M. Feacal calprotectin shedding after short term treatment with NSAIDs. Scand. J. Gastroenterol. 1996; 31: 339-344.
39. Dreiser, R. L., Riebenfeld, D. Nimesulide in the treatment of osteoarthritis. Double blind studies in comparison with piroxicam, ketoprofen and placebo. Drug 1993; 46 (SuppI 1): 191-195.
40. Fossaluzza, V., Montagnani, G. Efficacy and tolerability of nimesulide in elderly patients with osteoarthritis: double blind trial versus naproxen. J. Int. Med. Res. 1989; 17:295303.
41. Mêle, G., Memeo, A., Mellisi, L. et al. Post marketing surveillance on nimesulide in the treatment of 8354 patients over 60 years old affected with acute and chronic musculoskeletal diseases. Arch Med. Interna, (in Italian). 1992; 44: 213-21.
42. Pochobradsky, M. G., Mêle, G. Bretta, A. Post marketing survey of nimesulide in the short term treatment of osteoarthritis. Drug Exper. Clin. Res. 1991; 17: 197-204.